VMY-1-101

Overview

VMY-1-101 is a fluorescent cyclin-dependent kinase ( CDK ) inhibitor, with an excitation of 410 nm and emission of 512 nm. VMY-1-101 competitively inhibits ATP binding to CDKs. VMY-1-101 induces G2/M cell cycle arrest in human breast cancer cells. VMY-1-101 induces modest apoptosis in human breast cancer cells. VMY-1-101 blocks proliferation of human breast cancer cells, including multidrug resistance-positive cells, and is not a substrate for p-glycoprotein . VMY-1-101 localizes to the cytoplasm of human breast cancer cells. VMY-1-101 shows increased binding to human breast cancer tissue compared to fluorophore alone. VMY-1-101 can be used for the research of breast cancer .

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Breast Cancer | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Cancer > Cancer Drug Resistance | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Signaling Pathways > CDK | Products > Signaling Pathways > Apoptosis

Product Information

• Catalog No.: HY-182383
• CAS No.: 1209002-42-5
• Molecular Formula: C33H40ClN9O4S
• Molecular Weight: 694.25
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source